Find out more

Find out more about the work of our committee sub-groups and forums by clicking the logos below. These include The British Viral Hepatitis Group, British Association for the Study of the Liver Nurse Forum and the British Liver Transplant Group.

The British Viral Hepatitis aims to improve the management and study of patients with chronic viral liver disease, bringing together UK hepatologists, gastroenterologists, infectious disease physicians, virologists and interested epidemiologists.

British Association for the Study of the Liver Nurse Forum is a professional nursing organisation aiming to develop knowledge and understanding of liver disease, in order to improve the quality of patient care.

The BLTG (British Liver Transplant Group) was launched in 2014 to represent the professional interests of liver transplantation in the UK and promote strategic and academic development.



BASL ANNUAL MEETING, BLTG Transplant Meeting & BASLNF Meeting 2016
Manchester Central, 6-9 September

Annual Mtg
Mtg Only 
Abstracts Closed



BASL is a multi-disciplinary society with around 850 members composed of interested individuals from clinical medicine, clinical and basic research and allied professions. Your Annual subscription is used to organise the Annual Meeting held each September.

Members of BASL receive the following benefits:

  • discounted registration rates for the annual meeting and other relevant meetings
  • eligibility for the BASL Travel Awards (for members below status of Senior Lecturer or Consultant to allow presentation of high-quality UK liver research at International meetings, including the American Association for the Study of Liver Disease)
  • eligibility for the prestigious Dame Sheila Sherlock Award (to an emerging researcher in the field of liver disease, for members below status of Senior Lecturer or consultant). Applications are usually submitted to the BASL Committee three months prior to the annual meeting - details are announced.

Click here to find out more about joining us.


22/08/16 Study questions isolation of HCV patients during haemodialysis
News Type: Clinical News

A literature review has cast doubt on whether isolating HCV-infected patients during haemodialysis has any effect on transmission rates.

The Universidad Peruana Cayetano Heredia, Lima, Peru, found only one appropriate study. It covered 12 centres:  four used dedicated haemodialysis machines for HCV-infected patients and eight used non-dedicated machines. There were 593 patients enrolled. One centre was excluded after randomisation. Random sequence generation was not described and allocation concealment was not performed. Participants and personnel were not blinded and blinding of outcome assessors was not reported.

Only 74.5% of the patients were followed for nine months; and 47.3% were followed for an additional nine months. The authors only reported one outcome, measuring the difference in incidence of HCV in both groups. The authors did not consider the exposure time, to determine the adjusted rate of seroconversion risk/patient-year.

The study reported that the incidence of HCV infection during the first follow-up period (nine months) was 1.6% in the dedicated group, and 4.7% in the non-dedicated group (risk ratio 0.34). During the second 18 month follow-up the incidence was 1.3% in the dedicated group and 5.8% in the control group (risk ratio 0.22).

The reviewers wrote, “we found no differences in terms of the number of participants developing HCV infection when comparing the dedicated group with the usual care. Moreover, the evidence was of very low quality, which means that we have very little confidence in the effect estimate”. They concluded that the benefits and harms of isolating HCV-infected patients from other patients during haemodialysis are uncertain.


Isolation as a strategy for controlling the transmission of hepatitis C virus (HCV) infection in haemodialysis units.Bravo Zuñiga JI, Loza Munárriz C, López-Alcalde J. Cochrane Database Syst Rev. 2016 Aug 11;8 [Epub ahead of print]




22/08/16 Successful responses with Peg-INF for HCV patients on haemodialysis
News Type: Clinical News

In a new study amongst haemodialysis patients with HCV, pegylated interferon (Peg-INF) monotherapy resulted in high virological responses and was well-tolerated.

Researchers at New Delhi’s All India Institute of Medical Sciences studied 80 patients on dialysis with HCV infection who were treated with Peg-INF monotherapy. Those with genotype 1 and 4 were given 12 months therapy while those with genotypes 2 and 3 had six months. Mean time from diagnosis of HCV infection and the treatment start was 10.7 months.

Of the 80 patients, 43 had rapid virological responses (RVRs), while 49 had early virological and end of treatment responses. There was no difference related to genotype and 54 percent had sustained virological responses.

All patients had mild flu-like symptoms, 64 required increases in erythropoietin doses, 28developed leukopenia (three treatment-limiting) and 16 developed thrombocytopenia (one treatment-limiting). Five developed tuberculosis, five bacterial pneumonia, and one bacterial knee monoarthritis. None of the patients developed depression.


Pegylated interferon monotherapy for hepatitis C virus infection in patients on hemodialysis: A single center study. Agarwal SK, Bhowmik D, Mahajan S et al. Indian J Nephrol. 2016 Jul-Aug;26(4):244-51 


22/08/16 Routine testing gives earlier HCV detection in HIV-positive gay men
News Type: Clinical News

Routine anti-HCV testing at a sexually transmitted infection (STI) outpatient clinic led to earlier HCV detection among HIV-positive men who have sex with men (MSM).

In 2007, routine HCV antibody testing was introduced for MSM with an HIV-positive or unknown status attending a Dutch STI outpatient clinic. Researchers evaluated whether this screening resulted in additional and earlier HCV diagnoses among MSM who also attend HIV clinics.

At first STI consultation, HIV-positive MSM and MSM opting-out of HIV testing (HIV-status-unknown) were tested for HCV antibodies (anti-HCV). During follow-up consultations, only previously HCV-negative men were tested. Retrospectively, STI clinic and HIV clinic HCV diagnosis dates were compared.

At first consultation, 112 of 1,742 HIV-positive and three of 446 HIV-status-unknown MSM tested anti-HCV-positive. On follow-up, 32 HIV-positive MSM became anti-HCV-positive. Four of 34 HIV-positive MSM notified by their sexual partner of HCV tested anti-HCV-positive. Of 163 HIV-positive MSM with HCV antibodies, 78 reported a history of HCV.

HCV diagnosis data at the HIV clinic was requested for the remaining 85 MSM and available for 54 MSM. Of these 54, 28 were diagnosed with HCV at the STI clinic and seven concurrently with HIV. At their next scheduled HIV clinic consultation, three HCV cases probably would have been missed, the researchers suggested.


Earlier detection of hepatitis C virus infection through routine hepatitis C virus antibody screening of human immunodeficiency virus-positive men who have sex with men attending a sexually transmitted infection outpatient clinic: a longitudinal study. van Rooijen M, Heijman T, de Vrieze N et al. Sex Transm Dis. 2016 Sep;43(9):560-5 

22/08/16 The PBC Foundation - Sunday 11th September is World PBC day
News Type: BASL News

For 20 years The PBC Foundation has been supporting people diagnosed and living with Primary Biliary Cholangitis.

On Sunday 11th September it is World PBC day when members and supporters will be involved in many charitable activities. One of these will start at the close of the BASL conference on the 9th of September as Robert Mitchell-Thain and colleagues start a 3 Peaks Walk to raise funds for the charity.

Robert would welcome the support of BASL members who would like to join them for any section of the walk, with Scafell on Friday 9th September, Snowdon on Saturday 10th September and finishing on World PBC day with Ben Nevis on Sunday 11th September.

If you want to join any leg of the event, contact Robert through and if joining the event is not possible then please support their efforts through their Just Giving page; . ‎

19/08/16 Life Chances Strategy Briefing – AHA
News Type: BASL News

The Alcohol Health Alliance (AHA) campaigns for assurances that alcohol harm will be tackled in the government’s Life Chances Strategy.

August 2016: The AHA is working hard to ensure that the government’s forthcoming Life Chances Strategy will benefit all disadvantaged groups, including those suffering adverse consequences from alcohol, who make up a significant proportion of those needing support.

Click on the link > HERE to view their full briefing on the strategy.

If you have any questions please contact Laura McLeod, Policy and Advocacy Manager - Alcohol Health Alliance. Email - or Tel: 0203 815 8930.

15/08/16 Anti-viral therapy may cut sexual desire in HCV patients
News Type: Clinical News

Many HCV patients – especially men – receiving some anti-viral therapies lose sexual desire.

A total of 181 HCV patients at Taiwan’s China Medical University Hospital tertiary medical centre received peg-interferon (PegIFN)α2a or PegIFNα2b plus ribavirin (RBV), according to response-guide therapy for 24 to 48 weeks. Those with decreased sexual desire before PegIFNα plus RBV were excluded.

All were evaluated using the Mini-International Neuropsychiatric Interview and the 21-item Beck Depression Inventory (BDI). The 21st item of the BDI was used to evaluate decreased sexual desire.

During therapy, 124 of the 181 patients had decreased sexual desire. The BDI score peaked at 14.8 weeks and the severity was greatest at 16 weeks. The average score of the 21st item of the BDI correlated with decreased sexual desire. Depression history and the prevalence of subsequent major depressive disorder after anti-viral therapy was correlated to reduced sexual desire. Male patients complained more significantly than females.


Anti-viral therapy and decreased sexual desire in patients with chronic hepatitis C. Hsiao PJ, Hsieh PF, Chou EC et al. PLoS One. 2016 Aug 9;11(8): e0160450 

15/08/16 No added benefit with nurse-led treatment for HCV drug injectors
News Type: Clinical News

Nurse-led initiations of antiviral therapy have not lead to an increased uptake or adherence with treatment among people with HCV who inject drugs.

A study involving UK community clinics in London and Surrey compared nurse- and physician-initiated antiviral therapy with pegylated interferon and ribavirin.

Despite easy access to antiviral therapy, treatment uptake was poor, with no significant difference between the groups. The proportion of participants initiating treatment during follow-up was 10% with nurse-initiated (6/62) and 9% with physician-initiated (6/76) therapy. Adherence was similar in both groups, with only one patient in each not adhering to therapy. There were no serious adverse events, but interferon-related side effects were common. Drug and alcohol use did not change during therapy.


Community nurse-led initiation of antiviral therapy for chronic hepatitis C in people who inject drugs does not increase uptake of or adherence to treatment. Lewis H, Kunkel J, Axten D et al. Eur J Gastroenterol Hepatol. 2016 Aug 3. [Epub ahead of print]

15/08/16 High prevalence of cirrhosis and fibrosis in type 2 diabetics
News Type: Clinical News

People with type 2 diabetes often have undiagnosed advanced fibrosis and cirrhosis, a new study suggests (1).

Researchers at Pontificia Universidad Católica de Chile, Santiago, studied 145 type 2 patients (median age 60, mean BMI 29.6 kg/m2 and mean diabetes duration 7.6 years). 

There was a high rate of liver steatosis (63.9%), advanced fibrosis assessed by NAFLD fibrosis score (12.8%) and evidence of liver cirrhosis assessed by MRI (6.0%). In a multivariate analysis GGT > 82 IU/L and no alcohol intake were independently associated to advanced fibrosis.

A literature review suggested that metformin may improve the survival of diabetic patients with liver cancer (2).

The reviewers, from Central South University, Changsha, China, found 11 studies involving 3,452 liver cancer patients. Metformin use was associated with better survival (hazard ratio 0.59) of liver cancer patients, and the beneficial effect persisted (hazard ratio 0.64) when the population was restricted to diabetic liver cancer patients. Adjusting for age, etiology, index of tumour severity and treatment of liver cancer, the association between metformin use and better survival of liver cancer patients was stable. Pooled hazard ratios ranged from 0.47 to 0.57.

The reviewers warned that the results should be interpreted with caution because of possible residual confounding.


1.    High prevalence of undiagnosed liver cirrhosis and advanced fibrosis in type 2 diabetic patients. Arab JP, Barrera F, Gallego C et al. Ann Hepatol. 2016 Sep-Oct;15(5):721-8

2.    Metformin use improves survival of diabetic liver cancer patients: systematic review and meta-analysis. Ma SJ, Zheng YX, Zhou PC et al. Oncotarget. 2016 Aug 2 [Epub ahead of print]


01/09/16 - 03/09/16 2nd Sheila Sherlock updates in Hepatolgy 2016 meeting
News Type: BASL Endorsed Events


Venue: The Royal Free Hospital, London

This is the 2nd in a series of International meetings with the Sheila Sherlock brand aimed at renovating the tradition of the periodic updates introduced by Dame Sheila Sherlock at the Royal Free Hospital. This new series is dedicated to current fundamental themes in Hepatology that will be presented and discussed by the Royal Free Liver Specialists together with some of the most renown International speakers.

Full programme information can be downloaded here - Download Programme 1-3 Sept 2016.pdf .

To find out more information and how to Register for the event click > here

Please contact Lynn Knight if you have any questions -

06/09/16 - 07/09/16 BASL BLTG School of Transplantation - 6th & 7th Sept - FREE to BASL/BLTG members - Book Now
News Type: BASL Events

Venue: Manchester Central, Manchester

This two day event offers an excellent platform for trainees with lectures delivered by carefully selected leading speakers from the UK. The topics covered include liver transplant, acute liver failure, surgical aspects of liver transplantation and post-transplant management.

The programme compliments the BASL British Liver Transplant Group (BLTG) Meeting, which is taking place at the same venue, with great opportunities for interaction.

Delegates will be encouraged to attend the event over the two days, along with the BLTG themed sessions on the morning of Wednesday 7th September before the BASL Annual Meeting which starts on the afternoon of Wednesday 7th September.

The School is free to BASL Members (*a £40 refundable deposit will be taken on booking*) with the cost to Non-members of £45.

For delegates who register there is also the opportunity to have a one to one mentoring session with Dr Bill Griffiths - Addenbrookes Hospital Cambridge or Dr Mike Heneghan - Kings College Hospital, London. Each session will be 20 minutes and will cover advice on career development. To book a mentoring session please contact Kim Girling at BASL . There are 7 sessions available on a first come first served basis.

To view the 'draft' programme please click here >   Download BASL School Transplantation Programme.pdf

To book for the event click > here

* Overnight accomodation is not included. 

06/09/16 - 07/09/16 BLTG Transplant Meeting - September 2016 - BOOKING NOW OPEN
News Type: BASL Events

Venue - Manchester Central

The Chair of the BLTG, Professor Darius Mirza would like to invite you to the third meeting of the BLTG (British Liver Transplant Group).

As an affiliate of BASL, the BTLG has built on the role of the UK and Ireland Annual Meeting and will integrate the meetings previously organised by each individual transplant centre to offer a central stage for those operating in or with a strong interest in the field of liver transplantation.

This meeting will be linked to the BLTG Sessions and Williams-Calne Lecture within the BASL Annual Meeting programme on Wednesday 7th September; 08.30-13.00.

We hope that you will be present at this meeting, which will be attended by both eminent UK and international speakers, including Professor Mike Lucey, University of Wisconsin School of Medicine and Public Health, who will also deliver the distinguished Williams-Calne lecture.

The winner of the Andy Burroughs Young Investigator Award will deliver the prize lecture on 6th September 2016. 

REGISTRATION - all of the details including the programme can be found on the BASL / BLTG Annual Meeting website by clicking > here

07/09/16 - 09/09/16 BASL Annual Meeting 2016 - Book Your Place Today
News Type: BASL Events

Registration - OPEN 

Venue: Manchester Central, Manchester

VISIT THE BASL Annual Meeting 2016 website to find out Programme Information and to Register - CLICK HERE.

The BASL Annual Meeting is the highlight of the BASL calendar and the main liver meeting in the UK. This year we hope to attract in excess of 500 delegates, bringing together clinicians, nurses, scientists and all those interested in liver disease.

Eminent UK and overseas speakers converge to deliver an informative and exciting meeting over three days, which for September 2016 will take place at Manchester Central.

A preview of the programme can also be found >  Download Annual Meeting 2016 Programme Final.pdf

07/09/16 - 09/09/16 The 5th International Symposium on Hepatitis Care in Substance Users - Oslo, Norway
News Type: Other Events

This symposium is the leading International conference focused on the management of hepatitis among substance users. It is organised by the International Network for Hepatitis in Substance Users (INHSU). In 2015, INHSU decided to move to an annual symposium to keep pace with the rapid development of new therapies and exciting new research on HCV care among people who inject drugs. Hence, the 2016 INHSU symposium will be held in Oslo, Norway.

The International Symposium on Hepatitis in Substance Users attracts delegates including health professionals (doctors, nurses and allied health), researchers, community organisations, people who use drugs and policy makers.

Abstract submission is now open. Submit your abstract before Friday 22 April 2016.

For further information and to register click here

Contact details for the conference secretariat are as follows: 
P: +61 2 8204 0770

09/09/16 - 10/09/16 Coimbra Liver Transplantation Conference - Coimbra, Portugal
News Type: Other Events

Coimbra Liver Transplantation Conference - Coagulation Liver Disease and Liver Transplant Facts and Controversies

Event Content - Monothematic meeting will cover a variety of concepts in liver and coagulation, highlighting management before, during and after liver transplant.

Venue - Coimbra Paediatric Hospital Auditorium - Coimbra Hospital and University Centre

To find out more information click here

12/09/16 - 13/09/16 Edinburgh International Conference of Medicine: Past, Present & Future
News Type: Other Events

The Royal College of Physicians of Edinburgh (RCPE) and the Society for Acute Medicine (SAM) are delighted to be bringing you the most ambitious international programme on the past, present and future of medicine. This two-day conference will combine the historical aspects of medicine with a look to the future for healthcare across a broad range of clinical topics.

Venue: The Edinburgh International Conference Centre
Abstracts: now closed

For further information view here  Download Edinburgh International Conference of Medicine Past Present and Future.pdf

You will be able to design your own agenda for the conference, choosing from a comprehensive range of over 35 parallel sessions covering over 15 specialties, ranging from acute medicine, cardiology, care of the older patient, diabetes, neurology and respiratory to health & wellbeing, maternal medicine and patient involvement.

This conference is open to all healthcare professionals at all stages of their careers and is a great opportunity to keep up to date with the latest clinical research, opinions and innovations in medicine, as well as building your network.

The conference has been approved for 12 CPD points.

Full details on how to register and the programme are available by clicking here

22/09/16 - 24/09/16 APASL Single Topic Conference on Non-responders - Turkey
News Type: Other Events


You are invited to the APASL Single Topic Conference on Non-responders that will be held between 22nd – 24th September, 2016 at the Hilton Bosphorus Hotel, Istanbul, Turkey.

To find out full information about the conference visit the website > here.

Important deadlines to note are as follows:
Early Bird Registration deadline - 1 July 2016
Abstract deadline - 29 July 2016


Join BASL Ward Membership Today - £100 per annum for up to 5 members per ward.

Ward membership benefits include; access to the Nurse e-learning toolkits on the BASL website, reduced fees at BASL Events including the Nurses Day at the Annual Meeting in September.

To find out how to apply click here

NURSES TRAVEL BURSARY 2016 - additional places available.

We are delighted to announce that AbbVie UK Ltd is offering 30 bursaries to support nurses attending the BASL Annual Meeting 2016.
Due to not all of the bursary places being filled in the first round, we are inviting applications for the final 9 places.
The bursary application deadline is Monday 1st August 2016. Find out how to apply > here.

Click here to view the Events Newsletter - August
Click here to view the Newsletter - June 

Learning Toolkits

The BASL Nurse Toolkits were developed following conversations with nurse specialists. These and a later email survey identified training needs to help nurses meet the liver nurse competencies. To access the Learning Toolkits sign in as a BASL Member and click on Manage Account

Quick Links

BASL is connected to a number of national initiaives that you might be interested in.